Get the latest Science News and Discoveries

Approval of bimekizumab in the United States, an IL-17 A and F blocker with European approval for psoriatic arthritis. Dermatologists now have a range of choices for highly effective and safer options, both in biologics and orals.

Alice Gottlieb, MD, PhD, put a spotlight on recent studies and the current psoriasis treatment armamentarium for dermatology clinicians to consider.

None

Get the Android app